October 24, 2012
|Cytheris announces US Orphan Drug Designation for CYT107 for the treatment of Progressive Multifocal Leucoencephalopathy (PML)|
Cytheris is a privately held clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases. The company’s lead drug candidate, CYT107 (glycosylated r-hIL-7), is in clinical development for two targeted indications with urgent medical needs and no current treatments:
CYT107 is a critical growth factor for immune T cell recovery and enhancement. Clinical trials conducted on more than 240 patients have demonstrated the ability of CYT107 to expand and protect CD4+ and CD8+ T-cells in various pathologic conditions as well as a consistent safety and tolerability profile. Cytheris is based in Issy-les-Moulineaux, close to Paris and currently has 33 employees.